OXiGENE (OXGN) Receives Meeting Minutes from FDA Type C Meeting on ZYBRESTAT(TM)
Tweet
Share
E-mailGet Alerts OXGN Hot Sheet
Join SI Premium – FREE
OXiGENE (Nasdaq: OXGN) receives meeting minutes from FDA type c meeting on ZYBRESTAT(TM) anaplastic thyroid program.
The FDA is looking for added trial(s) with a survival endpoint, saying that the SPA is no longer in effect.
The FDA is looking for added trial(s) with a survival endpoint, saying that the SPA is no longer in effect.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Agenus drug combo shows 33% three-year survival in colorectal cancer
- Trilogy Metals signs $35.6M investment deal with U.S. Dept. of War
- Lucid Group names three executives to commercial, finance, marketing roles
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
